NAGE logo

Niagen Bioscience, Inc. Stock Price

NasdaqCM:NAGE Community·US$580.2m Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 32 Fair Values set on narratives written by author

NAGE Share Price Performance

US$7.18
3.91 (119.57%)
55.2% undervalued intrinsic discount
US$16.04
Fair Value
US$7.18
3.91 (119.57%)
55.2% undervalued intrinsic discount
US$16.04
Fair Value
Price US$7.18
AnalystConsensusTarget US$16.04

NAGE Community Narratives

AnalystConsensusTarget·
Fair Value US$16.04 55.2% undervalued intrinsic discount

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects

2users have liked this narrative
1users have commented on this narrative
15users have followed this narrative

Recent NAGE News & Updates

Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues

Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues

Wellness Adoption And Academic Trials Will Define Future Opportunity

Key Takeaways Expanding clinical credibility and global partnerships are opening new high-margin markets, broadening channels, and supporting scalable revenue growth with improved margins. Strong e-commerce performance and diversified product pipeline in preventive health provide resilience, reduced risk, and durable long-term earnings visibility.

Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash

Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash

Niagen Bioscience, Inc. Key Details

US$116.3m

Revenue

US$42.3m

Cost of Revenue

US$74.0m

Gross Profit

US$56.3m

Other Expenses

US$17.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.22
Gross Margin
63.62%
Net Profit Margin
15.24%
Debt/Equity Ratio
0%

Niagen Bioscience, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
3 Rewards

About NAGE

Founded
1999
Employees
104
CEO
Robert Fried
WebsiteView website
www.niagenbioscience.com

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.4%
  • 3 Months: 7.8%
  • 1 Year: 17.8%
  • Year to Date: 14.7%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 3.7%. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›